Post-marketing experiences with belimumab in the treatment of SLE patients

Rheumatic Disease Clinics of North America

Volumn 40, Issue 3, 2014, Pages 507-517

  Askanase, Anca D ^a   Yazdany, Jinoos ^b   Molta, Charles T ^c  

^a New York Presbyterian Morgan Stanley Children's Hospital   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c GLAXOSMITHKLINE   (United States)

Author keywords

Belimumab; Lupus; Observational studies; SLE

Indexed keywords

BELIMUMAB; COMPLEMENT; CORTICOSTEROID; DOUBLE STRANDED DNA; PLACEBO; PREDNISONE; B CELL ACTIVATING FACTOR; IMMUNOSUPPRESSIVE AGENT; MONOCLONAL ANTIBODY;

ADULT; ARTHRITIS; BRAIN DISEASE; BRAIN VASCULITIS; CONTROLLED STUDY; DEATH; DISEASE ACTIVITY; DISEASE COURSE; DISEASE EXACERBATION; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INFUSION; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HEALTH CARE QUALITY; HEALTH INSURANCE; HEART INFARCTION; HUMAN; INFECTION; INFLAMMATION; INFUSION RELATED REACTION; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; MYOSITIS; NEPHRITIS; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; PATIENT PREFERENCE; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; REVIEW; SCORING SYSTEM; STROKE LIKE SYMPTOM; SYSTEMIC LUPUS ERYTHEMATOSUS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; B-CELL ACTIVATING FACTOR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; OBSERVATIONAL STUDY AS TOPIC; PRODUCT SURVEILLANCE, POSTMARKETING; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84904391928     PISSN: 0889857X     EISSN: 15583163     Source Type: Journal    
DOI: 10.1016/j.rdc.2014.04.007     Document Type: Review

References (27)

1. Yazdany J., Erkan D., Sanchez-Guerrero J., et al. Post-marketing experience with belimumab in U.S. Lupus Centers: data from the Lupus Clinical Trials Consortium, Inc. (LCTC) National Patient Registry. Arthritis Rheum 2013, 65(10):1605. [abstract].
2. Askanase A., Reddy A., Buyon J.P., et al. Favorable clinical response to belimumab at three months. Arthritis Rheum 2013, 65(10):1574. [abstract].
3. Collins C., Dall'Era M., Oglesby A., et al. 12-month outcomes associated With Belimumab in patients with systemic lupus erythematosus in clinical practice settings: the observe study. Arthritis Rheum 2013, 65(10):1740. [abstract].
4. Tan E.M., Cohen A.S., Fries J.F., et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982, 25(11):1271-1277.
5. Urowitz M.B., Gladman D.D., Ibanez D., et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort. Arthritis Care Res (Hoboken) 2012, 64(1):132-137.
6. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997, 40(9):1725.
7. Lim S.S., Drenkard C., McCune W.J., et al. Population-based lupus registries: advancing our epidemiologic understanding. Arthritis Rheum 2009, 61(10):1462-1466.
8. Lim S.S., Bayakly A.R., Helmick C.G., et al. The incidence and prevalence of systemic lupus erythematosus, 2002-2004: the georgia lupus registry. Arthritis Rheumatol 2014, 66(2):357-368.
9. Somers E.C., Marder W., Cagnoli P., et al. Population-based incidence and prevalence of systemic lupus erythematosus: the michigan lupus epidemiology and surveillance program. Arthritis Rheumatol 2014, 66(2):369-378.
10. Askanase A.D., Wallace D.J., Weisman M.H., et al. Use of pharmacogenetics, enzymatic phenotyping, and metabolite monitoring to guide treatment with azathioprine in patients with systemic lupus erythematosus. JRheumatol 2009, 36(1):89-95.
11. Carneiro J.R., Sato E.I. Double blind, randomized, placebo controlled clinical trial of methotrexate in systemic lupus erythematosus. JRheumatol 1999, 26(6):1275-1279.
12. Nashi E., Wang Y., Diamond B. The role of B cells in lupus pathogenesis. Int J Biochem Cell Biol 2010, 42(4):543-550.
13. Baker K.P., Edwards B.M., Main S.H., et al. Generation and characterization of LymphoStat-B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator. Arthritis Rheum 2003, 48(11):3253-3265.
14. Zhang J., Roschke V., Baker K.P., et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. JImmunol 2001, 166(1):6-10.
15. Petri M., Stohl W., Chatham W., et al. Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus. Arthritis Rheum 2008, 58(8):2453-2459.
16. Furie R., Stohl W., Ginzler E.M., et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008, 10(5):R109.
17. Shum K., Askanase A. Belimumab and the clinical data. Curr Rheumatol Rep 2012, 14(4):310-317.
18. Wallace D.J., Stohl W., Furie R.A., et al. Aphase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Rheum 2009, 61(9):1168-1178.
19. Furie R.A., Petri M.A., Wallace D.J., et al. Novel evidence-based systemic lupus erythematosus responder index. Arthritis Rheum 2009, 61(9):1143-1151.
20. Jacobi A.M., Huang W., Wang T., et al. Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 2010, 62(1):201-210.
21. Bengtsson A.A. Belimumab in systemic lupus erythematosus - what can be learned from longterm observational studies?. JRheumatol 2014, 41(2):192-193.
22. Ginzler E.M., Wallace D.J., Merrill J.T., et al. Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus. JRheumatol 2014, 41(2):300-309.
23. Navarra S.V., Guzmán R.M., Gallacher A.E., et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial. Lancet 2011, 377(9767):721-731.
24. Furie R., Petri M., Zamani O., et al. Aphase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum 2011, 63(12):3918-3930.
25. van Vollenhoven R.F., Petri M.A., Cervera R., et al. Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response. Ann Rheum Dis 2012, 71(8):1343-1349.
26. Touma Z., Gladman D.D., Ibañez D., et al. Development and initial validation of the systemic lupus erythematosus disease activity index 2000 responder index 50. JRheumatol 2011, 38(2):275-284.
27. Fredericks C., Kvam K., Bear J., et al. Acase of progressive multifocal leukoencephalopathy in a lupus patient treated with belimumab. Lupus 2014, [Epub ahead of print].